Carmot Therapeutics Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
70
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$3.3B
Carmot Therapeutics General Information
Description
Carmot Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes. It has three clinical-stage product candidates are: CT-388, a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist for the treatment of obesity and type 2 diabetes (T2D); CT-996, a once-daily oral, small molecule GLP-1 receptor agonist for the treatment of obesity and T2D; and CT-868, a once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist for the treatment of type 1 diabetes (T1D) patients with overweight or obesity.
Contact Information
Website
www.carmot.us(Operating Subsidiary)
Corporate Office
- 740 Heinz Avenue
- Berkeley, CA 94710
- United States
Corporate Office
- 740 Heinz Avenue
- Berkeley, CA 94710
- United States
Carmot Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 26-Jan-2024 | $3.3B | Completed | Clinical Trials - Phase 2 | ||
| 10. IPO | 17-Nov-2023 | Cancelled | Clinical Trials - Phase 2 | |||
| 9. Later Stage VC (Series E) | 25-May-2023 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC (Series D) | 25-Jul-2022 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC (Series C) | 30-Sep-2020 | Completed | Clinical Trials - Phase 2 | |||
| 6. Debt - PPP | 03-May-2020 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC (Series B) | 17-Jan-2018 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series A) | 17-Jul-2012 | Completed | Startup | |||
| 3. Grant | 08-Dec-2011 | $300K | $300K | Completed | Startup | |
| 2. Grant | 31-Dec-2010 | $440K | $300K | Completed | Startup |
Carmot Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | ||||||||
| Series D1 | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 1,977,878 | $0.001000 | $0.51 | $6.37 | $6.37 | 1x | $6.37 | 3.64% |
| Series A | 3,431,745 | $0.001000 | $0.05 | $0.63 | $0.63 | 1x | $0.63 | 6.32% |
Carmot Therapeutics Comparisons
Industry
Financing
Details
Carmot Therapeutics Competitors (2)
One of Carmot Therapeutics’s 2 competitors is Gelesis Holdings, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gelesis Holdings | Formerly VC-backed | Boston, MA | ||||
| Regulus Therapeutics | Formerly VC-backed | San Diego, CA |
Carmot Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Carmot Therapeutics Patents
Carmot Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240390464-A1 | Treatment of adults with overweight or obesity with or without weight-related comorbidities | Pending | 21-May-2023 | ||
| US-20240366728-A1 | Treatment of diabetes mellitus | Pending | 23-Apr-2023 | ||
| US-20240425513-A1 | Oxazole, oxadiazole, and indole derivatives for the inhibition of usp28 | Pending | 22-Oct-2021 | ||
| EP-4419508-A2 | Oxazole, oxadiazole, and indole derivatives for the inhibition of usp28 | Pending | 22-Oct-2021 | ||
| US-20230151074-A1 | Modulators of g-protein coupled receptors | Pending | 13-May-2021 | C07K14/605 |
Carmot Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Carmot Therapeutics Former Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 5AM Ventures | Venture Capital | Minority | ||
| Amgen | Corporation | Minority | ||
| Deep Track Capital | Venture Capital | Minority | ||
| Franklin Templeton | Asset Manager | Minority | ||
| Frazier Lifesciences Acquisition | Special Purpose Acquisition Company (SPAC) | Minority |
Carmot Therapeutics FAQs
-
When was Carmot Therapeutics founded?
Carmot Therapeutics was founded in 2008.
-
Where is Carmot Therapeutics headquartered?
Carmot Therapeutics is headquartered in Berkeley, CA.
-
What is the size of Carmot Therapeutics?
Carmot Therapeutics has 70 total employees.
-
What industry is Carmot Therapeutics in?
Carmot Therapeutics’s primary industry is Biotechnology.
-
Is Carmot Therapeutics a private or public company?
Carmot Therapeutics is a Private company.
-
What is the current valuation of Carmot Therapeutics?
The current valuation of Carmot Therapeutics is .
-
What is Carmot Therapeutics’s current revenue?
The current revenue for Carmot Therapeutics is .
-
How much funding has Carmot Therapeutics raised over time?
Carmot Therapeutics has raised $374M.
-
Who are Carmot Therapeutics’s investors?
5AM Ventures, Amgen, Deep Track Capital, Franklin Templeton, and Frazier Lifesciences Acquisition are 5 of 19 investors who have invested in Carmot Therapeutics.
-
Who are Carmot Therapeutics’s competitors?
Gelesis Holdings and Regulus Therapeutics are competitors of Carmot Therapeutics.
-
When was Carmot Therapeutics acquired?
Carmot Therapeutics was acquired on 26-Jan-2024.
-
Who acquired Carmot Therapeutics?
Carmot Therapeutics was acquired by Roche.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
